Fulcrum Therapeutics
Insider trading & Transactions

Last updated:

Transaction Date Insider Security Shares Price per share Total value Source
Option
WALLACE OWEN B. officer: Chief Scientific Officer
 Stock Option (right to buy) 2,232 $7.84 $17,499
Sale
GOULD ROBERT J director, officer: See Remarks
 Common Stock 1,919 $20.01 $38,392
Option
CADAVID DIEGO officer: SVP Clinical Development
 Common Stock 600 $4.83 $2,898
Sale
CADAVID DIEGO officer: SVP Clinical Development
 Common Stock 600 $4.83 $2,898
Option
CADAVID DIEGO officer: SVP Clinical Development
 Stock Option (right to buy) 600 $4.83 $2,898
Option
WALLACE OWEN B. officer: Chief Scientific Officer
 Common Stock 448 $7.84 $3,512
Sale
WALLACE OWEN B. officer: Chief Scientific Officer
 Common Stock 448 $7.84 $3,512
Option
WALLACE OWEN B. officer: Chief Scientific Officer
 Stock Option (right to buy) 448 $7.84 $3,512
Sale
GOULD ROBERT J director, officer: See Remarks
 Common Stock 2,500 $20 $50,000
Option
WALLACE OWEN B. officer: Chief Scientific Officer
 Common Stock 412 $7.84 $3,230
Sale
WALLACE OWEN B. officer: Chief Scientific Officer
 Common Stock 412 $7.84 $3,230
Option
WALLACE OWEN B. officer: Chief Scientific Officer
 Stock Option (right to buy) 412 $7.84 $3,230
Option
CADAVID DIEGO officer: SVP Clinical Development
 Common Stock 1,860 $4.83 $8,984
Sale
CADAVID DIEGO officer: SVP Clinical Development
 Common Stock 1,860 $4.83 $8,984
Option
CADAVID DIEGO officer: SVP Clinical Development
 Stock Option (right to buy) 1,860 $4.83 $8,984
Sale
THOMSON PETER G. officer: VP Finance & Accounting
 Common Stock 7,500 $16 $120,000
Sale
CADAVID DIEGO officer: SVP Clinical Development
 Common Stock 2,143 $17.69 $37,912
Sale
THOMSON PETER G. officer: VP Finance & Accounting
 Common Stock 5,000 $6.2 $31,020
Option
WALLACE OWEN B. officer: Chief Scientific Officer
 Common Stock 6,088 N/A N/A
Sale
GOULD ROBERT J director, officer: See Remarks
 Common Stock 2,500 N/A N/A
Option
WALLACE OWEN B. officer: Chief Scientific Officer
 Stock Option (right to buy) 6,088 N/A N/A
Sale
WALLACE OWEN B. officer: Chief Scientific Officer
 Common Stock 6,088 N/A N/A
Sale
CADAVID DIEGO officer: SVP Clinical Development
 Common Stock 2,143 N/A N/A
Sale
THOMSON PETER G. officer: VP Finance & Accounting
 Common Stock 5,000 N/A N/A
Purchase
CASDIN CAPITAL, LLC 10 percent owner
 Common Stock 140,000 $15 $2,100,000
Purchase
SANOFI 10 percent owner
 Common Stock (par value $0.001) 93,750 $16 $1,500,000
Purchase
THIRD ROCK VENTURES III, L.P. 10 percent owner
 Common Stock 81,250 $16 $1,300,000
Purchase
THIRD ROCK VENTURES IV, L.P. 10 percent owner
 Common Stock 81,250 $16 $1,300,000
Purchase
6 DIMENSIONS CAPITAL, L.P. 10 percent owner
 Common Stock 118,750 $16 $1,900,000
Purchase
LEVIN MARK J director, 10 percent owner
 Common Stock 81,250 N/A N/A

Showing 100 to 130 of 130 results.

Insider trading

Monitoring trades made by the management members or major shareholders of companies may help create a sharper picture of what is happening inside the companies. Base your decisions on buys or sells of the people involved and do the right thing at the right time.

Who is insider?

Every director or senior officer, as well as any other entity or individual owning more than 10% of the company’s shares on the stock market, is called an insider. Such people or entities are allowed to buy/sell the company's shares under strictly controlled conditions. Key premise here is that none of them can make trades based on non-public information about the company.

Similar companies insider trading: